, “This conference was valuable for the novice, as well as those seasoned in PRO – with very informative speakers and great discussions.”
Pittsburgh, PA (PRWEB) April 23, 2011
invivodata inc.®, the industry leader in patient reported outcomes (PRO) solutions and services for global clinical research, along with its scientific and regulatory consulting division, PRO Consulting®, today announced the successful completion of its annual PRO conference in Fort Lauderdale, Fl. The conference – PROficiency™ 2011 – was designed to facilitate attendees’ understanding of the strategic and tactical considerations of PRO and ePRO throughout all phases of clinical development.
Over 35 global biopharmaceutical organizations sent representatives to the 2-day event, including clinical researchers, scientists, data managers, and regulatory specialists. Attendees were presented real-world PRO case studies and involved in discussions about successful PRO strategy design and clinical implementation. One attendee commented, “This conference was valuable for the novice, as well as those seasoned in PRO – with very informative speakers and great discussions.”
“The interest generated by PROficiency 2011 matches the increasing interest we are seeing in our PRO Consulting services, which assist clinical researchers in the strategies, concepts, and instruments for capturing PRO data in development programs,” said Doug Engfer, President & CEO of invivodata. “Considering the growing interest in PROs for clinical research and their regulatory implications, it’s no surprise that so many biopharmaceutical researchers are eager to learn more about the latest PRO strategies and trends.”
“We’re extremely pleased with the success of the conference,” said Bob Young, Chief Operating Officer for invivodata. “This annual conference marks the cornerstone of our ongoing educational PROficiency initiative, which is designed to answer many of the questions that clinical trial sponsors have about effectively using PRO in clinical research.”
The next installment of the PROficiency initiative is a Web Seminar on May 26, 2011. The webinar, “Is Your PRO Instrument Ready for Regulatory Evaluation?” will be presented by Dr. Jean Paty of PRO Consulting and will focus on the important elements of PRO data collection pertaining to current regulatory expectations. Interested parties can register for the webinar at http://www.invivodata.com/eweb/.
invivodata is the only fully-integrated PRO Solutions Organization delivering regulatory-proven strategic consulting and practical ePRO solutions to biopharmaceutical companies who depend upon patient-centered research. From crafting PRO measurement strategy to collecting PRO data electronically, invivodata helps its customers strategically use patient reported data to support labeling claims, enhance market access, and meet other clinical program objectives. Through partnerships with leading CROs and eClinical technology providers, invivodata seamlessly integrates into the clinical trial ecosystem, helping to minimize operational risk and maximize efficiencies. invivodata’s solutions have been used in over 300 clinical programs and are built upon the industry-leading ePRO system in delivering primary efficacy data for global drug approvals. invivodata inc. is a privately held company with global headquarters in Pittsburgh, PA., USA; its European headquarters is in London, England; and its technology development center is in Scotts Valley, CA., USA. For more information, visit http://www.invivodata.com.
About PRO Consulting
PRO Consulting, a division of invivodata, inc., provides consulting services to help clinical research teams effectively develop, execute, and document patient reported outcome (PRO) strategies to support their clinical research objectives. The PRO Consulting team has worked on over 150 clinical studies in 50+ indications, has more than 265 years of cumulative experience in psychometrics, PRO study design, and migrating and validating electronic solutions to collect PRO data, and has extensive experience working with the FDA and other regulatory bodies. For more information please visit http://www.patientreported.com
# # #